QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

Consortium has announced enrollment of its 1,000th participant, marking a major milestone for what is designed to be the largest and most inclusive prospective observational biobanking study in ALS.

Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig's disease, is an incurable neurological disorder affecting motor neurons—nerve cells in the brain and spinal cord that control voluntary muscle ...

AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meeting Study was a success showing masitinib to be a ...

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects neurons in the brain and spinal cord causing loss of muscle control. Scientists have now suggested a potential ...

The amyotrophic lateral sclerosis market is expected to grow owing to the increasing prevalence of the disease, along with the promising emerging pipeline therapies, such as Masitinib (AB Sciences), ...

Some patients with a rare form of ALS benefited from an experimental therapy, with biomarker evidence of reduced injury to neurons and even limited functional recovery. When Columbia neurologist and ...

Amylyx, the maker of a new drug to treat ALS, is pulling that drug from the market and laying off 70 percent of its workers after a large clinical trial found that the drug did not help patients, ...

Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones & ...